SparingVision
PrivateLast Round
Series B
Sep 14, 2022
Total Funding Raised
$130.49M
Company Overview
SparingVision operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Series B round in September 2022.
SparingVision is a biotechnology company developing genomic medicines and gene-agnostic therapies for inherited retinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SparingVision Comparables
Compare SparingVision with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nanoscope Therapeutics Inc. | 86% | |
| Coave Therapeutics | 86% | |
| Restore Vision Inc. | 85% |
For institutional investors. Book with your work email.
SparingVision Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 14, 2022 | ||||
| Series A | Oct 21, 2020 | ||||
| Grant | Jul 9, 2019 | ||||
| Grant | Jul 12, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SparingVision Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Programme d'Investissements d'Avenir | Series B |
| European Innovation Council Fund | Grant |
| Ministry of Higher Education and Research | Grant |
| Ysios Capital | Series A, Series B |
| 4BIO Capital | Series B, Series A |
| Sofimac Innovation | Series A |
| EIC Accelerator | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 9, 2025
Kalliopi 'Kali' Stasi appointed as the new Chief Medical Officer.
- May 19, 2025
Presented PRODYGY data and research update at ASGCT 2025.
For institutional investors. Book with your work email.
SparingVision Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SparingVision's valuation, stock price, and market status.
Is SparingVision a public or private company?
SparingVision is a private company.
What is the current stock price of SparingVision?
SparingVision is a private company, so its shares have no public market price. Caplight tracks SparingVision's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SparingVision worth (valuation)?
Valuation information for SparingVision is not publicly available.
Can I buy SparingVision stock?
SparingVision shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SparingVision's last funding round?
SparingVision's most recent funding round was Series B on September 14, 2022.
Who are the main investors in SparingVision?
Key investors in SparingVision include European Innovation Council Fund, Ministry of Higher Education and Research, 4BIO Capital, UPMC Enterprises, Jeito Capital.
Will SparingVision IPO soon?
No public IPO plans have been announced for SparingVision.
How can I track SparingVision secondary market activity?
Caplight tracks bids, offers, and trades in SparingVision's shares on secondary markets.